PO.MCB10.02 · 分子与细胞生物学
在乳腺癌研究中使用qPCR和ddPCR技术检测lncRNA的比较分析
Comparative analysis of lncRNA detection using qPCR and ddPCR technologies in breast cancer research
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
长链非编码RNA(lncRNA)是一类多样化的RNA分子(>200个核苷酸),具有有限的蛋白编码潜能。已鉴定出数千种lncRNA,然而大多数在功能上仍未被表征。这些分子在基因调控、染色质重塑和表观遗传控制中发挥关键作用。当其失调时,它们与癌症和其他疾病相关。其组织特异性表达使其成为有前景的生物标志物。但与mRNA相比,其低丰度给检测带来了重大挑战。敏感性是一个主要障碍,因为lncRNA的表达水平通常远低于mRNA,使准确定量变得困难。
传统的定量PCR(qPCR)已被广泛用于基因表达分析;然而,在检测诸如lncRNA等低丰度靶标时,其敏感性和精确性可能受限。相比之下,微滴数字PCR(ddPCR TM)提供绝对定量而无需依赖标准曲线,并展现出更优越的敏感性和重复性,尤其适用于稀有转录本。
在本研究中,我们比较了qPCR和ddPCR平台,使用多达七个靶标的检测组合,在MCF7雌激素受体阳性(ER+)细胞系及其他莫昔芬耐药衍生系(MCF7-TAMR)中对乳腺癌相关lncRNA进行分析,包括来自已验证组合的参考基因(HPRT1、RPL13a)。我们评估了敏感性、多重检测能力和工作流程效率。微滴数字PCR始终优于qPCR,为低丰度lncRNA提供更准确的基因表达测量。ddPCR平台可靠地实现了低至0.5拷贝/μL水平的绝对定量。它还能检测到细微的表达变化,甚至是低于两倍差异的变化。
优越的敏感性和多重检测能力使ddPCR技术特别适合于乳腺癌的早期检测和监测。这些结果表明,微滴数字PCR是生物标志物验证和转化研究的高度可靠工具。其先进的能力使其在检测诸如lncRNA等稀有转录本方面具有价值。选择正确的方法对于准确测量新的RNA靶标至关重要,而微滴数字PCR提供了绝对定量所需的可靠性。
查看英文原文 English abstract
Long noncoding RNAs (lncRNAs) are a diverse class of RNA molecules (>200 nucleotides) with limited protein-coding potential. Thousands of lncRNAs have been identified, however, most remain functionally uncharacterized. These molecules play critical roles in gene regulation, chromatin remodeling, and epigenetic control. When dysregulated, they are linked to cancer and other diseases. Their tissue-specific expression makes them promising biomarkers. But their low abundance compared to mRNAs creates significant challenges for detection. Sensitivity is a major obstacle, since lncRNAs are typically expressed at levels much lower than mRNAs, making accurate quantification difficult.
Conventional quantitative PCR (qPCR) has been widely used for gene expression analysis; however, its sensitivity and precision can be limiting when detecting low-abundance targets such as lncRNAs. Droplet digital PCR TM (ddPCR TM ), by contrast, offers absolute quantification without reliance on standard curves and demonstrates superior sensitivity and reproducibility, particularly for rare transcripts.
In this study, we compared qPCR and ddPCR platforms for profiling breast cancer associated lncRNAs using an assay panel of up to seven targets in the MCF7 estrogen receptor-positive (ER⁺) cell line and its Tamoxifen-resistant derivative (MCF7-TAMR), including reference genes (HPRT1, RPL13a) from validated panels. We evaluated sensitivity, multiplexing, and workflow efficiency. Droplet Digital PCR consistently outperformed qPCR, providing more accurate measurements of gene expression for low-abundance lncRNAs. The ddPCR platform reliably achieved absolute quantification at levels as low as 0.5 copies per µL. It also detected subtle changes in expression, even those below two-fold differences.
Superior sensitivity and multiplexing capabilities make ddPCR technology especially well-suited for the early detection and monitoring of breast cancer. These results demonstrate Droplet Digital PCR as a highly reliable tool for biomarker validation and translational research. Its advanced capabilities make it valuable for detecting rare transcripts such as lncRNAs. Selecting the right method is crucial for accurately measuring new RNA targets and Droplet Digital PCR offers the reliability needed for absolute quantification.
利益披露 Disclosure
S. Perike, None..
N. Kumar, None..
C. Shu, None..
A. Prantner, None..
A. P. Olcott, None..
E. J. Dreskin, None.